Overall, alterations impacting EGFR-PI3K-Akt-mTOR, NOTCH, NF-κB signaling and DNA repair pathways accounted for ~72% (n = 71/98) of the NPC samples analyzed, and may be useful to predict clinical benefit in NPC patients. This evidence concerns the gene MTOR and nasopharyngeal carcinoma.